search
Back to results

Use of a Microbial Sealant to Reduce Surgical Site Infections. (Integuseal)

Primary Purpose

Surgical Site Infection, SCIP

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Open Colorectal Surgery
Laparoscopic Surgery
Sponsored by
University of Southern California
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Surgical Site Infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Nonemergent colon and/or rectal abdominal surgical procedures
  2. Women of child-bearing potential must have a negative serum HCG assay prior to surgery
  3. Ages ≥18 years.

Exclusion Criteria:

  1. Known history of hypersensitivity to cyanoacrylate, formaldehyde or acetone products.
  2. Undergoing emergency surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed). Emergency surgery includes cases where standard bowel preparation and other preoperative assessments cannot be done.
  3. Undergoing a significant concomitant surgical procedure (e.g., Whipple & organ transplant surgery).

    The following concomitant procedures are allowed: appendectomy, cholecystectomy, oophorectomy, liver biopsy/wedge resection (but not liver resection), cystectomy.

  4. History of prior laparotomy within the last 60 days of this planned procedure.
  5. Planned to undergo a second laparotomy or colorectal surgical procedure (e.g. colostomy or ileostomy takedown) within 60 days of this planned first procedure.
  6. Evidence preoperatively of any of the following: sepsis, severe sepsis, or septic shock (note that SIRS alone is not an exclusion criteria).6, 7
  7. Preoperative severe neutropenia defined as total neutrophil count ≤500 × 106/L.
  8. Current abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy or for any reason.
  9. Receiving antibiotic therapy within the 1 week prior to the date of surgery.
  10. Preoperative evaluation suggests intra-abdominal process that might preclude full closure of the skin.
  11. Preoperative serum creatinine > 3 mg/dL or renal failure requiring dialysis.
  12. History of ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer.
  13. History of major organ transplantation, including bone marrow transplantation.
  14. Taking systemic steroids >10 mg prednisone daily or remicade within 2 weeks prior to surgery or a history of a current immunosuppressive condition (eg, symptomatic HIV infection), defined as a CD4 count < 200.
  15. Pregnant, lactating, or of childbearing potential not practicing a birth control method with a high degree of reliability (defined in section 3.1).
  16. Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated.

Sites / Locations

  • Los Angeles County/USC Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Microbial Sealant

Control

Arm Description

Integuseal (Kimberly Clark)

No microbial sealant

Outcomes

Primary Outcome Measures

Incidence of SSI with and without microbial sealant.
Determine the rate of SSI when microbial sealant (InteguSEAL© Kimberly-Clark) is used compared to control (no microbial sealant).

Secondary Outcome Measures

Subgroup incidence of SSI with and without microbial sealant
Compare SSI for open vs. laparoscopy colectomy, age, BMI, diabetes and morbidity (ASA class), hospital readmission, reoperation and wound dehiscence with and without microbial sealant.

Full Information

First Posted
September 13, 2014
Last Updated
September 13, 2014
Sponsor
University of Southern California
search

1. Study Identification

Unique Protocol Identification Number
NCT02241915
Brief Title
Use of a Microbial Sealant to Reduce Surgical Site Infections.
Acronym
Integuseal
Official Title
Microbial Sealants Do Not Decrease Surgical Site Infection for Clean Contaminated Colorectal Procedures.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Southern California

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Surgical site infections (SSI) are costly complications that may cause significant morbidity and increase the cost of care, particularly in colorectal surgery. Microbial sealants (MS) are a new class of wound barriers aimed at decreasing SSI, however there is only evidence of benefit in clean Class 1 procedures. Based on its success in Class 1 procedures, we hypothesized that a microbial sealant could reduce the rate of SSI by half for clean contaminated colorectal procedures (Class 2).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Site Infection, SCIP

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Microbial Sealant
Arm Type
Active Comparator
Arm Description
Integuseal (Kimberly Clark)
Arm Title
Control
Arm Type
Sham Comparator
Arm Description
No microbial sealant
Intervention Type
Procedure
Intervention Name(s)
Open Colorectal Surgery
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Surgery
Primary Outcome Measure Information:
Title
Incidence of SSI with and without microbial sealant.
Description
Determine the rate of SSI when microbial sealant (InteguSEAL© Kimberly-Clark) is used compared to control (no microbial sealant).
Time Frame
15 Months
Secondary Outcome Measure Information:
Title
Subgroup incidence of SSI with and without microbial sealant
Description
Compare SSI for open vs. laparoscopy colectomy, age, BMI, diabetes and morbidity (ASA class), hospital readmission, reoperation and wound dehiscence with and without microbial sealant.
Time Frame
15 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Nonemergent colon and/or rectal abdominal surgical procedures Women of child-bearing potential must have a negative serum HCG assay prior to surgery Ages ≥18 years. Exclusion Criteria: Known history of hypersensitivity to cyanoacrylate, formaldehyde or acetone products. Undergoing emergency surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed). Emergency surgery includes cases where standard bowel preparation and other preoperative assessments cannot be done. Undergoing a significant concomitant surgical procedure (e.g., Whipple & organ transplant surgery). The following concomitant procedures are allowed: appendectomy, cholecystectomy, oophorectomy, liver biopsy/wedge resection (but not liver resection), cystectomy. History of prior laparotomy within the last 60 days of this planned procedure. Planned to undergo a second laparotomy or colorectal surgical procedure (e.g. colostomy or ileostomy takedown) within 60 days of this planned first procedure. Evidence preoperatively of any of the following: sepsis, severe sepsis, or septic shock (note that SIRS alone is not an exclusion criteria).6, 7 Preoperative severe neutropenia defined as total neutrophil count ≤500 × 106/L. Current abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy or for any reason. Receiving antibiotic therapy within the 1 week prior to the date of surgery. Preoperative evaluation suggests intra-abdominal process that might preclude full closure of the skin. Preoperative serum creatinine > 3 mg/dL or renal failure requiring dialysis. History of ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer. History of major organ transplantation, including bone marrow transplantation. Taking systemic steroids >10 mg prednisone daily or remicade within 2 weeks prior to surgery or a history of a current immunosuppressive condition (eg, symptomatic HIV infection), defined as a CD4 count < 200. Pregnant, lactating, or of childbearing potential not practicing a birth control method with a high degree of reliability (defined in section 3.1). Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated.
Facility Information:
Facility Name
Los Angeles County/USC Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Use of a Microbial Sealant to Reduce Surgical Site Infections.

We'll reach out to this number within 24 hrs